Vitamin K1 100 mcg by Bluebonnet — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Caplet(s) Serving Size

100 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K1

100 mcg (83% DV)

✅ Within RDA (0.8× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.1mg

Other Ingredients

Calcium Phosphate Stearic Acid Magnesium Stearate Vegetable Cellulose Vegetable Glaze

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Vegan Vegetarian Adult (18 - 50 Years) Kosher No Allergies Gluten Free Dairy Free Sugar Free

Product Information

📋 Directions for Use

Directions: As a dietary supplement, take one caplet daily or as directed by a healthcare practitioner.

⚠️ Warnings & Precautions

Caution: If you are on blood-thinning medication, this product is not recommended. Consult physician if pregnant/nursing, taking medication, or have a medical condition.

For adults only. Keep out of reach of children.

🧪 Formulation Notes

Bluebonnet's Vitamin K1 100 mcg Caplets are formulated with vitamin K1 (phylloquinone) in its crystalline form to help support bone health.

May support bone health

Free of milk, egg, fish, crustacean shellfish, tree nuts, peanuts, wheat, soybeans and sesame. Also free of corn, gluten, barley, rice and sugar.

Bluebonnet's KOF-K Certification #K-0000700

Made with Non GMO ingredients

Bone health

Vegan

KOF-K Parve (Kosher)

Gluten free

Additional Information

Made with Non GMO ingredients KOF-K Parve (Kosher) Vegan

Store tightly closed in a cool, dry place.

Product Details

UPC / SKU 7 43715 00650 8

DSLD Entry Date 2025-05-21

Product Type Vitamin

Form Other (e.g. tea bag)

Brand Bluebonnet

DSLD ID 332793

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation